Amyloid, Tau, APOE4
Two proteins, one gene, decades of disease
Alzheimer's pathology centres on two proteins that misbehave — amyloid-beta forming plaques between neurons, and tau forming tangles inside them — and one genetic variant (APOE4) that markedly affects risk. Understanding the trio makes the treatment landscape of the 2020s make sense.
Amyloid: the first domino
Amyloid-beta is a protein fragment normally cleared during sleep via the glymphatic system. Clearance slows with age; amyloid accumulates and forms plaques that disrupt synaptic function. Plaques begin forming 15–20 years before symptoms. Sleep + vascular health + APOE genotype all affect clearance rate.
Tau: the symptom driver
Tau tangles — misfolded versions of a normal structural protein — form inside neurons and trigger their death. Tau pathology correlates with cognitive decline much more tightly than amyloid does. The amyloid-tau-clinical-decline cascade is the modern framework.
APOE4: the risk multiplier
APOE has three common variants: ε2, ε3, ε4. One copy of APOE4 roughly triples Alzheimer's risk; two copies (~2–3% of the population) multiplies it by ~12. APOE4 affects lipid transport, amyloid clearance, and inflammation in the brain. Knowing your APOE genotype is a one-time test with lifelong implications — like Lp(a).
True or False
If you're APOE4-positive, getting Alzheimer's is inevitable.
This step is interactive — open the Thier app to try it.
Key Takeaway
Amyloid loads the gun, tau pulls the trigger, APOE4 shortens the fuse. All three have actionable implications. Testing APOE status is a useful data point for risk-stratified prevention — especially for APOE4 carriers who benefit most from aggressive sleep, vascular, and metabolic optimisation.